Revolution Medicines Offers Daraxonrasib via Expanded Access Program After Positive Pancreatic Cancer Trial

Amy Johnston, a 35-year-old office administrator and mother of three in Gilbertsville, Pennsylvania, was diagnosed with pancreatic cancer in 2025. She has completed chemotherapy and surgery and is now enrolled in a clinical trial. She expects to learn by the end of June 2026 whether that treatment is working.

If the trial results are negative, Johnston and her physician plan to seek daraxonrasib, a drug developed by Revolution Medicines. In a clinical trial, daraxonrasib nearly doubled overall survival time for pancreatic cancer patients. The company is now offering the drug through an expanded access program for patients outside formal studies.

She expressed concern that demand may exceed supply. “This is such a small company, and I worry their production is not able to keep up with the need,” she said. Bureaucratic requirements have already delayed access for some patients seeking the drug through the expanded access program.

Johnston questioned how allocation decisions will be made. “Who receives it first? Will it be for those who the drug is the last resort? ” she said. @statnews reported the details of Johnston’s case and the status of daraxonrasib access.